Current Report Filing (8-k)
June 21 2018 - 4:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2018
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-34655
|
|
04-3581650
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
One Broadway, 14th Floor
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 588-1960
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On June 18, 2018, AVEO Pharmaceuticals, Inc.
(the Company) held its 2018 Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting, the Companys stockholders voted on the following proposals:
1. The following nominees were elected to the Companys Board of Directors for terms expiring at the 2019 annual meeting of stockholders.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-
Votes
|
|
Mr. Michael P. Bailey
|
|
|
49,464,917
|
|
|
|
305,265
|
|
|
|
49,543,430
|
|
Mr. Kenneth M. Bate
|
|
|
47,837,807
|
|
|
|
1,932,375
|
|
|
|
49,543,430
|
|
Dr. Anthony B. Evnin
|
|
|
49,459,199
|
|
|
|
310,983
|
|
|
|
49,543,430
|
|
Mr. John H. Johnson
|
|
|
48,179,436
|
|
|
|
1,590,746
|
|
|
|
49,543,430
|
|
Dr. Robert C. Young
|
|
|
49,366,496
|
|
|
|
403,686
|
|
|
|
49,543,430
|
|
2. A
non-binding,
advisory proposal on the compensation of the Companys named
executive officers was approved.
|
|
|
|
|
For:
|
|
|
48,704,579
|
|
Against:
|
|
|
783,037
|
|
Abstain:
|
|
|
282,566
|
|
Broker
Non-Votes:
|
|
|
49,543,430
|
|
3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the
fiscal year ending December 31, 2018 was ratified.
|
|
|
|
|
For:
|
|
|
98,604,832
|
|
Against:
|
|
|
498,600
|
|
Abstain:
|
|
|
210,180
|
|
Broker
Non-Votes:
|
|
|
0
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AVEO Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Matthew Dallas
|
|
|
|
|
|
|
Matthew Dallas
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
Date: June 21, 2018
|
|
|
|
|
|
|
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jul 2024 to Aug 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2023 to Aug 2024